Analysts have been eager to weigh in on the Healthcare sector with new ratings on TG Therapeutics (TGTX – Research Report), Zoetis (ZTS – Research Report) and Teladoc (TDOC – Research Report).
TG Therapeutics (TGTX)
In a report released today, Alec Stranahan from Bank of America Securities maintained a Sell rating on TG Therapeutics, with a price target of $7.00. The company’s shares closed last Monday at $15.18.
According to TipRanks.com, Stranahan is a 3-star analyst with an average return of
TG Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $28.40.
See the top stocks recommended by analysts >>
Zoetis (ZTS)
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Zoetis, with a price target of $205.00. The company’s shares closed last Monday at $196.69, close to its 52-week high of $201.92.
According to TipRanks.com, Ryskin is a 3-star analyst with an average return of
Zoetis has an analyst consensus of Strong Buy, with a price target consensus of $228.00, which is a 15.3% upside from current levels. In a report released yesterday, Stifel Nicolaus also maintained a Buy rating on the stock with a $215.00 price target.
Teladoc (TDOC)
In a report released today, Allen Lutz from Bank of America Securities maintained a Hold rating on Teladoc, with a price target of $24.00. The company’s shares closed last Monday at $21.10.
According to TipRanks.com, Lutz is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Teladoc with a $24.13 average price target, implying a 17.1% upside from current levels. In a report issued on January 30, TD Cowen also maintained a Hold rating on the stock with a $22.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TGTX:
- Precision gets initial $7.5M from TG Therapeutics for azer-cel development
- TG Therapeutics participates in a conference call with Cantor Fitzgerald
- TG Therapeutics price target raised to $29 from $24 at B. Riley
- TG Therapeutics price target lowered to $22 from $23 at JPMorgan
- TG Therapeutics price target raised to $39 from $37.50 at Ladenburg
